ORIGINAL ARTICLE
Year : 2020  |  Volume : 32  |  Issue : 2  |  Page : 73-74

Lessons learned from the POUT trial: Adjuvant chemotherapy does improve the outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma


1 Center of Robotic and Endoscopic Urology, Athens Medical Center, Athens, Greece
2 Department of Urology, Bichat-Claude Bernard Hospital, Paris, France

Correspondence Address:
Evanguelos Xylinas
Department of Urology, Bichat-Claude Bernard Hospital, Paris
France
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/HUAJ.HUAJ_8_20

Rights and Permissions

Introduction: The management of patients with upper tract urothelial carcinoma (UTUC) is challenging, with radical nephroureterectomy (RNU) being the gold standard of treatment for high-risk disease. The role of chemotherapy is unclear. The POUT trial is a multicenter UK effort that addresses whether adjuvant chemotherapy improves disease-free survival (DFS) in patients with locally advanced and/or node-positive UTUC. Methods: The POUT trial enrolled 262 patients with UTUC (pT2-T4, N0-3, and M0) between 2012 and 2017. The patients were randomized (1:1) to four cycles of adjuvant gemcitabine–cisplatine (gemcitabine–carboplatin if GFR 30–49 ml/s) or surveillance following RNU. The patients were followed with cross-sectional imaging and cystoscopy every 6 months for the first 2 years and then annually for 5 years. The primary end point was DFS, whereas recurrence-free survival (RFS), overall survival (OS), toxicity, and quality of life (QoL) were the secondary end points. Results: The intent-to-treat analysis was conducted in 262 patients (131 chemotherapy and 131 surveillance). Among the patients treated with chemotherapy, 66% were offered gem-cis, while 68% completed successfully the four planned chemotherapy cycles. Approximately 50% of the patients undergoing chemotherapy developed Grade 3 or greater adverse events. A significant improvement in DFS (hazard ratio [HR]: 0.49 [confidence interval (CI): 0.31–0.76], P = 0.001) was observed at a median follow-up of 17.3 months. Considering the secondary end points, adjuvant chemotherapy was also associated with an improvement in RFS (HR: 0.49 [CI: 0.30–0.78], P = 0.02). Following adjustment for nodal involvement, the difference was more pronounced with a HR: 0.47 (CI: 0.30–0.74), P = 0.001. A difference in the OS curves favoring the adjuvant chemotherapy arm was noticed, but the difference remained nonsignificant due to short follow-up. Conclusions: The POUT trial provides exciting and convincing Level I evidence on the benefit associated with adjuvant chemotherapy administration in patients with locally invasive or node-positive UTUC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed731    
    Printed20    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal